BTKC481S介导的慢性淋巴细胞白血病对伊布替尼的耐药
该研究纳入四项伊布替尼序贯研究的患者,对复发患者回顾性及对筛查人群前瞻性进行BTK和PLCG2深度测序。中位随访3.4年,4年进展累积发生率为19%,复发患者中85%检出获得性BTK或PLCG2突变,突变中位检出时间早于复发9.3个月。前瞻性筛查中8例复发患者均在复发前检出耐药突变,另8例未达临床复发标准者亦检出突变。
要点
- 中位随访3.4年,4年进展累积发生率为19%(95%CI 14%–24%)。
- 复发患者中85%(95%CI 71%–94%)检出BTK或PLCG2获得性突变,突变中位早于复发9.3个月检出。
- 前瞻性筛查中8例复发患者均在复发前检出耐药突变,另8例未达临床复发标准者亦检出突变。
核心结论
- 伊布替尼治疗后慢性淋巴细胞白血病复发是临床意义日益增加的问题,BTK和PLCG2突变出现较早,有潜力作为未来复发的生物标志物,提示存在干预机会。
研究设计与样本
- 分析纳入四项伊布替尼序贯研究的患者,对复发患者回顾性、对筛查人群前瞻性进行BTK和PLCG2深度测序。
主要发现
- 中位随访3.4年,4年进展累积发生率为19%(95%CI 14%–24%)。
- 基线核型复杂、del(17)(p13.1)阳性及年龄小于65岁为进展的危险因素。
- 复发患者中85%(95%CI 71%–94%)检出BTK或PLCG2获得性突变,突变中位检出时间早于复发9.3个月(95%CI 7.6–11.7个月)。
- 前瞻性筛查的112例患者中8例复发,均在复发前检出获得性耐药突变;另8例尚未达临床复发标准者亦检出耐药突变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift in therapy, and relapse has been uncommon with current follow-up. Acquired mutations in BTK and PLCG2 can cause relapse, but data regarding the prevalence and natural history of these mutations are limited. Patients and Methods Patients accrued to four sequential studies of ibrutinib were included in these analyses. Deep sequencing for BTK and PLCG2 was performed retrospectively on patients who experienced relapse and prospectively on a screening population. Results With a median follow-up time of 3.4 years, the estimated cumulative incidence of progression at 4 years is 19% (95% CI, 14% to 24%). Baseline karyotypic complexity, presence of del(17)(p13.1), and age less than 65 years were risk factors for progression. Among patients who experienced relapse, acquired mutations of BTK or PLCG2 were found in 85% (95% CI, 71% to 94%), and these mutations were detected an estimated median of 9.3 months (95% CI, 7.6 to 11.7 months) before relapse. Of a group of 112 patients examined prospectively, eight patients have experienced relapse, and all of these patients had acquired resistance mutations before relapse. A resistance mutation was detected in an additional eight patients who have not yet met criteria for clinical relapse. Conclusion Relapse of chronic lymphocytic leukemia after ibrutinib is an issue of increasing clinical significance. We show that mutations in BTK and PLCG2 appear early and have the potential to be used as a biomarker for future relapse, suggesting an opportunity for intervention.
引用
- Woyach JA, Ruppert AS, Guinn D, et al. BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol. 2017. PMID: 28418267. doi:10.1200/JCO.2016.70.2282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。